Viatris Acquires Pacira BioSciences, Adding EXPAREL and iovera° to Portfolio
Viatris completes Pacira BioSciences acquisition, adding EXPAREL and iovera° and triggering NDA transfer and manufacturing integration work.


Post-merger integration timelines for EXPAREL and iovera° now move from planning to execution following Viatris Inc.'s completion of its acquisition of Pacira BioSciences on November 17, 2026, a transaction first announced October 8, 2026, at $36.50 per share in cash.
For QA directors and regulatory affairs leads, the immediate operational question is NDA ownership transfer and manufacturing site continuity. Pacira continues as a wholly owned subsidiary under the merger structure executed via Section 251(h) of the Delaware General Corporation Law, which means existing site registrations, approved processes, and supply agreements remain nominally intact at close, but post-merger harmonisation under ICH Q10 and 21 CFR Part 211 will require deliberate change control sequencing to avoid disrupting sterility assurance for EXPAREL's liposomal bupivacaine formulation.
Approximately 32.9 million shares, representing 66.46% of outstanding shares, were tendered before the November 16 expiration. Remaining shares were converted to the offer price through the short-form merger, with Pacira shares simultaneously delisted from the Nasdaq Global Select Market. Viatris projects the acquisition will contribute $90 million to $100 million in total revenues for the stub period from November 17 through December 31, 2026.
The non-opioid pain management category carries its own regulatory complexity: EXPAREL holds a biologics-adjacent manufacturing profile given its DepoFoam drug delivery platform, and any site consolidation decisions will require prior approval supplements under 21 CFR Part 314 before changes take effect. Supply continuity planning for hospital and ambulatory surgery center accounts will be a near-term pressure point for supply chain leads managing demand forecasting across the combined network.
The revenue contribution window through year-end provides a narrow but measurable baseline against which Viatris will calibrate integration pacing and resource allocation into 2027.
Source: Viatris Inc. via PR Newswire, November 17, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding

Innate Pharma Achieves Phase 1 Milestone for IPH4502 ADC with Linker Stability Signal

Discussion